Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05366881
Other study ID # Adela-EDMRD-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 3, 2022
Est. completion date December 2026

Study information

Verified date February 2024
Source Adela, Inc
Contact Brian Allen, MS
Phone 203-514-4155
Email brian.allen@adelabio.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate). These cancers were selected based on the existing clinical landscape and treatment availability.


Description:

This is an observational case-control study that includes individuals with cancer and individuals without known cancer. All participants will have clinical follow-up after enrollment. A subset of individuals with cancer will also have longitudinal blood sampling to evaluate the ability of the genome-wide methylome enrichment platform to detect minimal residual disease. This includes individuals with Stage I-III breast, colorectal, lung, or prostate cancer (Tier 1 Cancers). At baseline, all participants will provide a blood sample and applicable clinical data. Participants with a Tier 1 cancer will have clinical follow-up and blood draws after the completion of first-line treatment, every 3 months for the first year after first-line treatment, and every 6 months for an additional 2 years. All other cases will have clinical follow-up once a year for 3 years after enrollment. Control participants will have clinical follow-up every 6 months for up to 3 years from enrollment to evaluate cancer status. The blood test to be used in this study is a highly sensitive, epigenomic-based genome-wide methylome enrichment platform. The assay includes bisulfite-free, non-degradative genome-wide DNA methylation profiling from small quantities of cell-free DNA (cfDNA). Libraries constructed from cfDNA are enriched for methylated CpGs and preserve the native fragment length. This is followed by high throughput sequencing. For all assays, samples from participants with cancer and participants without cancer will be run together to reduce batch effects using methodology determined by the Sponsor. Results from the liquid biopsy test will not be returned to clinicians or participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 7000
Est. completion date December 2026
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Case Inclusion Criteria: - Newly diagnosed (within 90 days) with cancer or a recurrence of a cancer diagnosed >5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma - Able and willing to provide informed consent - =40 years of age Case Exclusion Criteria: - Currently receiving any treatment for cancer - Currently taking any demethylating agents/DNA hypomethylating agents - Simultaneously diagnosed with two or more invasive cancers - Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years - Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer - Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g. MGUS) in addition to the index cancer - Women who are known to be pregnant (self-reported) Control Inclusion Criteria - Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed) - Able and willing to provide informed consent - =40 years of age Control Exclusion Criteria - Currently receiving any treatment for cancer - Currently taking any demethylating agents/DNA hypomethylating agents - Women who are known to be pregnant (self-reported)

Study Design


Related Conditions & MeSH terms

  • Bladder Cancer
  • Brain Cancer
  • Brain Neoplasms
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Endometrial Neoplasms
  • Esophageal Cancer
  • Head and Neck Cancer
  • Hepatobiliary Cancer
  • Kidney Neoplasms
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Neoplasm, Residual
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cancer
  • Sarcoma
  • Stomach Cancer
  • Stomach Neoplasms
  • Thyroid Cancer

Locations

Country Name City State
United States Elligo Health Research, Inc. Austin Texas
United States Cleveland Clinic Cleveland Ohio
United States Baptist Corbin Corbin Kentucky
United States City of Hope Duarte California
United States Baptist Hardin Elizabethtown Kentucky
United States McLeod Health Florence South Carolina
United States North Georgia Health System Gainesville Georgia
United States Baptist Lexington Lexington Kentucky
United States Baptist (BHMCC) Memphis Tennessee
United States Miami Cancer Institute Miami Florida
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee
United States Baptist Floyd New Albany Indiana
United States Baptist Paducah Paducah Kentucky
United States Oregon Health Sciences University Portland Oregon
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Adela, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detection of cancer Differentiation of cancer signals from cases and non-cancer signals from controls based on analysis of cfDNA using the genome-wide methylome enrichment platform 24 months
Secondary Detection of specific cancer types Differentiation of cancer signals from cases with a specific cancer type and non-cancer signals from controls based on analysis of cfDNA using the genome-wide methylome enrichment platform 24 months
Secondary Tissue of origin Identification of the correct tissue of origin (as determined by clinical diagnosis) for cancer cases based on analysis of cfDNA using the genome-wide methylome enrichment platform 18 months
Secondary Clinical outcomes Recurrence-free survival and overall survival among cancer cases 54 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2